LB
Late-breaking Abstracts
Thursday, June 2, 2022: 5:00 PM-7:00 PM
Prince George's Exhibit Hall (Gaylord National Resort & Convention Center)
Use of Calcitonin Gene-Related Peptide Monoclonal Antibody Agents for the Treatment of Chronic or Episodic Migraine in Patients with Multiple Sclerosis
Zuleyma Toledo-Nieves, MD, University of South Florida Morsani College of Medicine;
Ashley Mason, BA, University of South Florida Morsani College of Medicine;
Derrick Robertson, MD, University of South Florida Morsani College of Medicine;
Angela Aungst, MPH, Multiple Sclerosis Division Department of Neurology University of South Florida;
Janice Maldonado, MD, University of South Florida Morsani College of Medicine
A 20-Year Review of Race and Ethnicity in Multiple Sclerosis Rehabilitation Trials: Work in Progress
Afolasade Fakolade, PhD, Queen's University;
Nadine Akbar, PhD, Queen's University;
Ashwaq Alqahtani, PhD(c), Queen's University;
Sumaya Mehelay, BSc(c), Queen's University;
Siona Phadke, BSc(c), Queen's University;
Matthew Tang, BSc(c), Queen's University;
Abdul Kareem Pullattayil, MIS, Queen's University;
Monica Busse, PhD, Cardiff University
Hypogammaglobulinemia Complicating Post-Acute Sequelae of COVID-19 (PASC).
Robert C Coppola, D.O., Multiple Sclerosis Center, University of Miami;
Kottil Rammohan, MD, Multiple Sclerosis Center, University of Miami;
Micheline McCarthy, MD, PhD, University of Miami Miller School of Medicine;
Melissa Ortega, MD, University of Miami;
Flavia Nelson, MD, University of Miami;
Ramon C Flores-Gonzalez, MD, University of Miami
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated with Mayzent (siponimod): An OTIS Observational Pregnancy Surveillance Study
Diana Johnson, M.S., University of California San Diego;
Ronghui Xu, PhD, MA, University of California San Diego;
Yunjun Luo, MS, University of California San Diego;
Jane Adams, PhD, University of Massachusetts;
Kenneth L Jones, MD, University of California San Diego;
Robert Felix, BA, University of California San Diego;
Christina Chambers, PhD, MPH, University of California San Diego
The Differential Impact of Ocrelizumab Versus Rituximab on Lymphocyte Count, Immunoglobulins, and Infection Rate
Collin Jakubecz, PharmD, University Hospitals Home Care Services;
Veronica Mears, PharmD, University Hospitals Home Care Services;
Alessandro Serra, MD, PhD, University Hospitals Cleveland Medical Center;
Hesham Abboud, MD, PhD, Case Western Reserve School of Medicine - - Cleveland Heights, OH
Incidence of Hypogammaglobulinemia in Patients Receiving Ocrelizumab or Rituximab for the Treatment of MS and Nmosd
Veronica Mears, PharmD, University Hospitals Home Care Services;
Collin Jakubecz, PharmD, University Hospitals Home Care Services;
Alessandro Serra, MD, PhD, University Hospitals Cleveland Medical Center;
Hesham Abboud, MD, PhD, Case Western Reserve School of Medicine - - Cleveland Heights, OH
Can a Shared Decision Making Tool Improve Multiple Sclerosis Dmt Utilization? the MS-Support Decision Aid
Nananda F Col, MD, MPH, MPP, FACP, Shared Decision Making Resources;
Andrew J Solomon, MD, University of Vermont College of Medicine;
Enrique Alvarez, MD, PhD, MSCI, University of Colorado;
Lori Pbert, PhD, University of Massachusetts Chan Medical School;
Carolina Ionete, MD, PhD, University of Massachusetts Memorial Medical Center;
Idanis Berrios-Morales, MD, University of Massachusetts Memorial Medical Center;
Jennifer Chester, FNP-BC, MSCN, Kansas City MS Center at College Park Specialty;
Christen Kutz, PhD, PA-C, Colorado Springs Neurological Associates;
Crystal Iwuchukwu, RN, BSN, FNP, Southeast Health;
Terrie Livingston, PharmD, EMD Serono, Inc., an affiliate of Merck KGaA;
Vicky Springmann, MSc, Shared Decision Making Resources;
Hannah V Col, MS (c), University of Maryland, Shared Decision Making Resources;
Long H Ngo, , PhD, Beth Israel Deaconess Medical Center
Stature: A Prospective Observational Study of the Relationship between Oral Dmt Burden and Adherence in People with MS
Michelle A Allan, RN MNurs(NP), Monash Health;
Lisa B Grech, PhD, MPsych, University of Melbourne;
Adriana Cartwright, BA, St Vincent's Hospital;
Joshua J Mardan, BPsychSc(Hons), Assoc MAPS, Monash Univeristy;
Janet Harding, N/A, Monash Univeristy;
Tim O'Maley, M.N.Sc (NP) B.H.Sc; Grad Cert Management; NNC, Princess Alexandra Hospital;
Sharryn Savickas, RN, Barwon Health;
Meena Sharma, RN MNurs(NP), Liverpool Hospital;
Paul Stockle, BNurse, Centre for Neuroscience Innovation;
Bronwyn Coulton, RN MNurs(NP), Eastern Health;
Belinda Bardsley, RN BN MSCN Dip Management, MS Nurses Australasia Incorporated;
Ernest Butler, MD, PhD, Monash Health
Actigraphy for Detection of Clinical Disability Progression in Multiple Sclerosis: Preliminary Analysis of a Prospective Study
Nicole Bou Rjeily, MD, Johns Hopkins University School of Medicine;
Chen Hu, MS, Johns Hopkins University School of Medicine;
Blake E Dewey, PhD, Johns Hopkins University School of Medicine;
Christy Hulett, BA, Johns Hopkins University School of Medicine;
Gabriella Dagher, BS, Johns Hopkins University School of Medicine;
Alexandra Zambriczki Lee, BS, Johns Hopkins University School of Medicine;
Alyssandra Valenzuela, BS, Johns Hopkins University School of Medicine;
Erin Brennan, MSN, PMHNP-BC, Johns Hopkins University School of Medicine;
Anna DuVal, BA, MPH, Johns Hopkins University School of Medicine;
Peter A Calabresi, MD, Johns Hopkins University School of Medicine;
Vadim Zipunnikov, PhD, Johns Hopkins University Bloomberg School of Public Health;
Kathryn C Fitzgerald, ScD, Johns Hopkins University School of Medicine;
Ellen M Mowry, MD, MCR, Johns Hopkins School of Medicine
Glatiramer Acetate Depot (Extended-Release) Phase IIa Study in Patients with Primary Progressive Multiple Sclerosis: Safety and Efficacy 1 Year Interim Snapshot Analysis
Shlomo Flechter, MD, Sheba Medical Center;
Laura Popper, MD, Mapi Pharma Ltd.;
Nadav Bleich Kimelman, DMD, PhD, Mapi Pharma Ltd.;
Shai Rubnov, PhD, Mapi Pharma Ltd.;
Uri Danon, B.Sc., MBA, Mapi Pharma Ltd.;
Ehud Marom, B.Sc., Mapi Pharma Ltd.;
Ron Milo, MD, Barzilai University Medical Center, Ben-Gurion University of the Negev;
Ronit Gilad, MD, Kaplan Medical Center;
Boaz Weller, MD, Bnai Zion Medical Center;
Adi Vaknin-Dembinsky, MD, Hadassah Medical Center;
Mark Hellmann, MD, Rabin Medical Center, Belinson Hospital;
Alla Shifrin, MD, Rambam Medical Center;
Arnon Karni, MD, Tel Aviv Sourasky Medical Center, Tel Aviv University
COVID-19 Vaccine Antibody Response in RMS Patients Treated with Ponesimod: Results from the Long-Term Extension Study AC-058B202
Janice Wong, MD, Janssen Research & Development, LLC;
Nina Hertoghs, PhD, Janssen Research & Development, LLC;
Alexandre Lemle, PharmD, MSc, Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies of Johnson & Johnson;
Philippe Linscheid, PhD, Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies of Johnson & Johnson;
Magdalena Pirozek Lawniczek, MD, Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies of Johnson & Johnson;
Nandini Raghavan, PhD, Janssen Research & Development, LLC;
Amita Singh, PhD, Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies of Johnson & Johnson;
Tatiana Sidorenko, MD, PhD, Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies of Johnson & Johnson
Treatment of Acute Optic Neuritis and MS Relapses: A Survey of Clinician Attitudes, Perspectives, and Clinical Reasoning
Emily M Schorr, MD, Johns Hopkins School of Medicine;
Nicole Bou Rjeily, MD, Johns Hopkins School of Medicine;
Alexander Brandt, MD, University of California, Irvine, School of Medicine;
Vivek Patel, MD, USC Roski Eye Inst., Keck School of Medicine;
Laura Balcer, MD MSCE, New York University Grossman School of Medicine;
June Halper, MSN, APN-C, MSCN, FAAN, Consortium of Multiple Sclerosis Centers;
Mark S Freedman, MSc, MD, University of Ottawa;
Friedemann Paul, MD, Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité Universitätsmedizin Berlin;
Pablo Villoslada, MD, PhD, Stanford University;
Ann Yeh, M.D., The Hospital for Sick Children;
Robert A Bermel, MD, Mellen Center for MS, Cleveland Clinic;
Axel Petzold, MD, PhD, UCL Institute of Neurology;
Jennifer Graves, MD PhD MAS, University of California San Diego;
Philipp Albrecht, MD, Heinrich Heine University Dusseldorf;
Rachel Nolan-Kenney, BA, New York University Grossman School of Medicine;
Peter Calabresi, MD, Johns Hopkins School of Medicine;
Ellen M Mowry, MD, MCR, Johns Hopkins School of Medicine;
Scott D. Newsome, DO, MSCS, FAAN, FANA, Johns Hopkins School of Medicine;
Kathryn C Fitzgerald, ScD, Johns Hopkins School of Medicine;
Shiv Saidha, MBBCh, MD, MRCPI, Johns Hopkins School of Medicine
Efficacy of Ofatumumab in Treatment-Naive, First-Switch and Late-Switch Patients: Insights from the Alithios Open-Label Extension Study
Jeffrey A Cohen, Dr., Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic;
Ralf Gold, MD, Department of Neurology, St Josef-Hospital, Ruhr-University Bochum;
Jerome De Seze, Dr., University Hospital of Strasbourg;
Derrick S Robertson, MD, Multiple Sclerosis Division, Department of Neurology, University of South Florida;
Heinz Wiendl, MD, MPH, University of Muenster;
Sibyl Wray, MD, Hope Neurology MS center;
Francesco Sacca, MD, NSRO Department, University “Federico II” of Naples;
Amin Azmon, PhD, Novartis Pharma A.G.;
Miriam King, BA (Hons), Novartis Pharma A.G.;
Simone Fantaccini, MD, Novartis Pharma A.G.;
Ronald Zielman, MD, PhD, Novartis Pharma B.V.;
Ludwig Kappos, MD, Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel
A Long Acting B Cell Depleting BiTE (Bi-Specific T Cell Engager) Significantly Ameliorated EAE Symptoms without Potential CRS Risk
Yu (Yvonne) Wen, PhD, Shenzhen Enduring Biotech, Princeton Enduring Biotech;
Shuangyu Tan, MS, Shenzhen Enduring Biotech;
Weidong Lyu, PhD, Shenzhen Enduring Biotech;
Qiudong Zhuo, BS, Shenzhen Enduring Biotech;
Yang Lei, MS, Shenzhen Enduring Biotech;
Zibin Wu, MS, Shenzhen Enduring Biotech;
Shuqiang Yin, PhD, Shenzhen Enduring Biotech;
Liling Zheng, MS, Shenzhen Enduring Biotech;
Dechun Wu, MS, Shenzhen Enduring Biotech, Princeton Enduring Biotech;
Shumin (Sam) Liu, PhD, Shenzhen Enduring Biotech, Princeton Enduring Biotech
Long-Term Efficacy for Patients Receiving Cladribine Tablets (3.5 mg/kg Over 2 years) in Clarity/Clarity Extension: A Post Hoc Analysis of Classic-MS
Gavin Giovannoni, MD, PhD, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London;
Thomas P. Leist, MD, Division of Clinical Neuroimmunology, Jefferson University;
Aida Aydemir, MD, EMD Serono Research & Development Institute, Inc.;
Elisabetta Verdun di Cantogno, MD, PhD, EMD Serono Research & Development Institute, Inc.
Connect Trial of Online Professional Esupport Groups for Black and Latinx People Living with MS
Amanda Cohen, MA, eSupport Health, PBC;
Joseph E. Duncan, MA, eSupport Health, PBC;
Amanda Speights, PhD, eSupport Health, PBC;
Victoria M Leavitt, PhD, eSupport Health
Spinal Cord Atrophy As a Marker of Disability Progression: Beyond Trial Data
Blake E Dewey, PhD, Johns Hopkins University School of Medicine;
Nicole Bou Rjeily, MD, Johns Hopkins University School of Medicine;
Chen Hu, MS, Johns Hopkins University School of Medicine;
Christy Hulett, BA, Johns Hopkins University School of Medicine;
Gabriella Dagher, BS, Johns Hopkins University School of Medicine;
Alexandra Zambriczki Lee, BS, Johns Hopkins University School of Medicine;
Alyssandra Valenzuela, BS, Johns Hopkins University School of Medicine;
Erin Brennan, MSN, PMHNP-BC, Johns Hopkins University School of Medicine;
Anna DuVal, BA, MPH, Johns Hopkins University School of Medicine;
Peter A Calabresi, MD, Johns Hopkins University School of Medicine;
Vadim Zipunnikov, PhD, Johns Hopkins University Bloomberg School of Public Health;
Kathryn C Fitzgerald, ScD, Johns Hopkins University School of Medicine;
Ellen M Mowry, MD, MCR, Johns Hopkins School of Medicine
RRMS Patients Treated with Natalizumab Report Better Outcomes and Treatment Satisfaction Than Patients Treated with Ocrelizumab
Regina Berkovich, MD, PhD, Neurology Program, Los Angeles County & USC Medical Center;
John Foley, MD, Rocky Mountain MS Clinic;
Mark Gudesblatt, MD, South Shore Neurologic Associates;
John Kramer, PA-C, St. Thomas Medical Partners-Neurology;
Hanyue Li, PhD, Biogen;
Zhaonan Sun, PhD, Biogen;
Kevin Benny, BS, MyMSTeam;
Beth Schneider, PhD, MyMSTeam;
Danette Rutledge, BSP, PhD, Biogen;
Robin L. Avila, PhD, Biogen
Estimating Time Saved in MS Clinic Using MS Smart Forms to Retrieve Clinical Data
Shuvro Roy, MD, Johns Hopkins University School of Medicine;
Thomas Grader-Beck, MD, PhD, Johns Hopkins Universisty;
Harinoor Mann, MD, Allegheny Health Network;
Maulik Kantawala, MD, Allegheny Health Network;
Kathryn C Fitzgerald, ScD, Johns Hopkins School of Medicine;
Thomas F Scott, MD, Drexel University College of Medicine;
Ellen M Mowry, MD, MCR, Johns Hopkins School of Medicine
Patient-Reported Outcomes from NOVA: A Randomized Controlled Study of the Efficacy of Natalizumab 6-Week Dosing Vs Continued 4-Week Dosing for MS
Lana Zhovtis Ryerson, MD, Department of Neurology, NYU Langone Health, New York University;
Gilles Defer, MD, Department of Neurology, Centre Hospitalier Universitaire de Caen;
Jeffrey A Cohen, MD, Mellen MS Center, Cleveland Clinic;
Douglas L Arnold, MD, Montreal Neurological Institute, McGill University, and NeuroRx Research;
Helmut Butzkueven, MBBS, PhD, Department of Neuroscience, Central Clinical School, Monash University;
Gary Cutter, PhD, University of Alabama School of Public Health;
Gavin Giovannoni, MD, PhD, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London;
Joep Killestein, MD, PhD, Department of Neurology, MS Centre Amsterdam, VU University Medical Centre;
Heinz Wiendl, MD, MPH, University of Muenster;
John Foley, MD, Rocky Mountain MS Clinic;
George Kong, PhD, Biogen;
Susie Sinks, PhD, Biogen;
Robert Kuhelj, PhD, Biogen;
Tyler Lasky, PharmD, Biogen;
Karthik Bodhinathan, PhD, Biogen
Nasal Anti-CD3 Monoclonal Antibody (Foralumab) Reduces PET Microglial Activation and Blood Inflammatory Biomarkers in a Patient with Non-Active Secondary Progressive MS
Tanuja Chitnis, MD, Harvard Medical School, Brigham and Women's Hospital;
Tarun Singhal, MD, Brigham and Women's Hospital, Harvard Medical School;
Jonathan Zurawski, MD, Harvard Medical School, Brigham and Women's Hospital;
Taylor J. Saraceno, BSc, Brigham and Women's Hospital;
John M. Sullivan, PA-C, Brigham and Women's Hospital;
Shrishti Saxena, MSc, Brigham and Women's Hospital;
Clare Baecher-Allan, PhD, Brigham and Women's Hospital;
Kunwar Shailubhai, PhD, MBA, Tiziana Life Sciences;
Howard L. Weiner, MD, Brigham and Women's Hospital, Harvard Medical School
COVID-19 Breakthrough Infections Among Persons with Multiple Sclerosis Vaccinated Against Sars-Cov-2
Caroline K Geiger, PhD, Genentech, Inc.;
Danny Sheinson, PhD, Genentech, Inc.;
Denise Boudreau, PhD, Genentech, Inc.;
Carmen Ng, PhD, Genentech, Inc.;
Preeti Bajaj, PhD, Genentech, Inc.
MRI Use in MS Clinical Practice: Results of the 2022 CMSC Survey
Anthony Traboulsee, MD, FRCPC, University of British Columbia;
Lori Saslow, MA, Consortium of MS Centers;
Mike Wattjes, MD PhD, Hannover Medical School;
Alex Rovira, MD, Hospital Universitari Vall d'Hebron, Autonomous University of Barcelona;
Jiwon Oh, MD PhD FRCPC, St. Michael’s Hospital, Univ of Toronto;
Daniel Reich, MD PhD, National Institutes of Health;
Scott D. Newsome, DO, MSCS, FAAN, FANA, Johns Hopkins School of Medicine;
Mara Rocca, MD, PhD, Vita-Salute San Raffaele University;
Jaume Sastre-Garriga, MD, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona;
June Halper, MSN, APN-C, MSCN, FAAN, Consortium of Multiple Sclerosis Centers;
Frederik Barkhof, MD, PhD, Institutes of Neurology and Healthcare Engineering, UCL;
David KB Li, MD FRCPC, University of British Columbia
Healthcare Experiences and Medical Mistrust Among People with Multiple Sclerosis: The Role of Racism and Social Deprivation
Jagriti 'Jackie' Bhattarai, PhD, MS, Assistant Professor, Johns Hopkins School of Medicine;
Kimystian Harrison, MD, Postdoctoral Fellow, Johns Hopkins School of Medicine;
Victoria A Levasseur, Postdoctoral Fellow, Washington University School of Medicine in St. Louis;
Abbey J Hughes, PhD, MS, Assistant Professor, Johns Hopkins University School of Medicine
Wearing-Off Effect Towards the End of Treatment Cycles in MS Patients Receiving High-Efficacy Dmts – Data from Social Media Listening
Joanne Fielding, PhD, Central clinical school, Monash University;
Marie Serceau, MS, Real Chemistry;
Janine Robinson, Associate Director, Integrated Intelligence Leader, Linguistics & Behavioral Science Center of Excellence, Real Chemistry;
Ivan Clement, Associate RWE director, Novartis Healthcare Pvt. Ltd.;
Chinmay Deshpande, PhD, BPharm, Novartis Pharmaceuticals Corporation
